Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (272K) Freely available
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Rice, J. C.
Right arrow Articles by Futscher, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rice, J. C.
Right arrow Articles by Futscher, B. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2000, Vol. 28, No. 17 3233-3239
© 2000 Oxford University Press

Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter

Judd C. Rice1 and Bernard W. Futscher1,2,*

1Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ 85721, USA and 2Bone Marrow Transplant Program, Arizona Cancer Center, Tucson, AZ 85724, USA

BRCA1 expression is repressed by aberrant cytosine methylation in sporadic breast cancer. We hypothesized that aberrant cytosine methylation of the BRCA1 promoter was associated with the transcriptionally repressive effects of histone hypoacetylation and chromatin condensation. To address this question, we developed an in vitro model of study using normal cells and sporadic breast cancer cells with known levels of BRCA1 transcript to produce a 1.4 kb 5-methylcytosine map of the BRCA1 5' CpG island. While all cell types were densely methylated upstream of –728 relative to BRCA1 transcription start, all normal and BRCA1 expressing cells were non-methylated downstream of –728 suggesting that this region contains the functional BRCA1 5' regulatory region. In contrast, the non-BRCA1 expressing UACC3199 cells were completely methylated at all 75 CpGs. Chromatin immunoprecipitations showed that the UACC3199 cells were hypoacetylated at both histones H3 and H4 in the BRCA1 promoter compared to non-methylated BRCA1 expressing cells. The chromatin of the methylated UACC3199 BRCA1 promoter was inaccessible to DNA–protein interactions. These data indicate that the epigenetic effects of aberrant cytosine methylation, histone hypoacetylation and chromatin condensation act together in a discrete region of the BRCA1 5' CpG island to repress BRCA1 transcription in sporadic breast cancer.

* To whom correspondence should be addressed at: Arizona Cancer Center, Tucson, AZ 85724, USA. Tel: +1 520 626 4646; Fax: +1 520 626 2415; Email: bfutscher@azcc.arizona.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene
PNAS, April 1, 2008; 105(13): 5160 - 5165.


Home page
 Nucleic Acids ResHome page
E. Auriol, L.-M. Billard, F. Magdinier, and R. Dante
Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus
Nucleic Acids Res., July 28, 2005; 33(13): 4243 - 4254.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
A. M. Bode and Z. Dong
Inducible Covalent Posttranslational Modification of Histone H3
Sci. Signal., April 26, 2005; 2005(281): re4 - re4.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Yuan, R. Z. Luo, S. Fujii, L. Wang, W. Hu, M. Andreeff, Y. Pan, M. Kadota, M. Oshimura, A. A. Sahin, et al.
Aberrant Methylation and Silencing of ARHI, an Imprinted Tumor Suppressor Gene in which the Function Is Lost in Breast Cancers
Cancer Res., July 15, 2003; 63(14): 4174 - 4180.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Toyota, Y. Sasaki, A. Satoh, K. Ogi, T. Kikuchi, H. Suzuki, H. Mita, N. Tanaka, F. Itoh, J.-P. J. Issa, et al.
Epigenetic inactivation of CHFR in human tumors
PNAS, June 24, 2003; 100(13): 7818 - 7823.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Thakur, T. Nakamura, G. Calin, A. Russo, J. F. Tamburrino, M. Shimizu, G. Baldassarre, S. Battista, A. Fusco, R. P. Wassell, et al.
Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors
Mol. Cell. Biol., June 1, 2003; 23(11): 3774 - 3787.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
J. C. Rice, K. Nishioka, K. Sarma, R. Steward, D. Reinberg, and C. D. Allis
Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes
Genes & Dev., September 1, 2002; 16(17): 2225 - 2230.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. Ballestar and M. Esteller
The impact of chromatin in human cancer: linking DNA methylation to gene silencing
Carcinogenesis, July 1, 2002; 23(7): 1103 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. M. Stimson and P. M. Vertino
Methylation-mediated Silencing of TMS1/ASC Is Accompanied by Histone Hypoacetylation and CpG Island-localized Changes in Chromatin Architecture
J. Biol. Chem., February 8, 2002; 277(7): 4951 - 4958.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J. F Costello and C. Plass
Methylation matters
J. Med. Genet., May 1, 2001; 38(5): 285 - 303.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.